Expanding Horizons: Benda Subsidiary Developing Potential AIDS Vaccine (China)
This article was originally published in PharmAsia News
China's Benda Pharmaceutical has announced its SiBiono subsidiary will work to produce a gene therapy treatment for AIDS. SiBiono is teaming up with DNAVEC, a Japanese research institute, to develop the prospective therapy. DNAVEC has agreed to give SiBiono the Chinese development and distribution rights to its experimental gene therapy vaccine SeV-Gag. This agreement would provide SiBiono entry into China's $14 billion AIDS treatment market. In return, SiBiono will allow DNAVEC access to its gene therapy platform for the production of SeV-Gag. As part of the agreement, SiBiono will also be responsible for all trials and approval processes of the drug in China. Benda is one of the country's top producers of both traditional and Western medicines. It is also the first company in the world to market gene therapy as a method for fighting cancer. (Click here for more
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.